AEterna Zentaris Reports Third Quarter 2008 Financial and Operati... ( All amounts are in U.S. dollars ....)

AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results

Date:11/13/2008

All amounts are in U.S. dollars

QUEBEC CITY, Nov. 13 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the third quarter ended September 30, 2008.

Third Quarter 2008 Highlights

- Appointment on September 1, 2008, of Juergen Engel, Ph.D. as President

and CEO of AEterna Zentaris, replacing Juergen Ernst who had been

acting as Interim President and CEO since April 2008. Mr. Ernst, the

former Chairman of the Company, was appointed Executive Chairman

effective September 1, 2008;

- Completion of patient recruitment for the second efficacy trial of the

Phase 3 program in benign prostatic hyperplasia (BPH) with lead

compound, cetrorelix;

- Start of second stage of recruitment for the Phase 2 trial in ovarian

cancer with AEZS-108. The trial is part of a Phase 2 program in

gynaecological cancers which will include up to 82 women;

- Signing of a license and cooperation agreement for the

commercialization of cetrorelix in BPH, with Handok Pharmaceuticals

Co., Ltd. (Handok) for the Korean market. Subsequent to quarter end,

signing of another agreement with Handok for the commercialization of

ozarelix in BPH for the Korean market; and

- Recovery of worldwide rights from Ardana plc (LSE: ARA) for the Growth

Hormone Secretagogue (GHS) compound, AEZS-130. Future development

options are currently being evaluated for the use of this compound in

growth hormone deficiencies.

Subsequent to Quarter-End

On November 11, 2008, AEterna Ze
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. AEterna Zentaris to Announce Third Quarter 2008 Financial and Operating Results on November 13, 2008
2. AEterna Zentaris Agrees to Sell Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
3. AEterna Zentaris Reaches 2nd Stage of Patient Recruitment for Phase 2 Trial in Endometrial Cancer with the Innovative LHRH Receptor Targeted Conjugate, AEZS-108
4. AEterna Zentaris to Present at Upcoming Oppenheimer 19th Annual Healthcare Conference
5. AEterna Zentaris Receives Notification from Nasdaq Relating to Minimum Bid Price
6. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris to Present at BioContact Quebec on October 2, 2008
8. AEterna Zentaris to Present at Upcoming CIBC World Markets 7th Annual Eastern Investor Conference
9. AEterna Zentaris Reports Second Quarter 2008 Financial and Operating Results
10. AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
11. AEterna Zentaris to Announce Second Quarter 2008 Financial and Operating Results on August 12, 2008

Post Your Comments:

AEterna Zentaris Reports Third Quarter 2008 Financial and Operati...( All amounts are in U.S. dollars ....)